Home    Back

Ro0506997    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica4
46Malignant rheumatoid arthritis1

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-004519-43-DE
(EUCTR)		29/05/200709/02/2007Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisPhase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis Relapsing Multiple SclerosisProduct Code: RO0506997
Product Code: RO0506997
Product Code: RO0506997		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes		200Phase 2United Kingdom;Czech Republic;Germany;Spain
2EUCTR2004-004519-43-SK
(EUCTR)		20/03/200713/02/2007Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisPhase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis Relapsing Multiple SclerosisProduct Code: RO0506997
Product Code: RO0506997
Product Code: RO0506997		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes		200Phase 2Czech Republic;Slovakia;Spain;Germany;United Kingdom
3EUCTR2004-004519-43-GB
(EUCTR)		07/03/200708/07/2005Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisPhase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis Relapsing Multiple SclerosisProduct Code: RO0506997
Product Code: RO0506997
Product Code: RO0506997		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes		200Phase 2Germany;Czech Republic;United Kingdom;Spain
4EUCTR2004-004519-43-CZ
(EUCTR)		12/01/200504/02/2005Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisPhase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis Relapsing Multiple SclerosisProduct Code: RO0506997
Product Code: RO0506997
Product Code: RO0506997		F. Hoffmann-La Roche LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		200Phase 2Germany;United Kingdom;Czech Republic;Spain

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-004022-27-ES
(EUCTR)		24/03/200504/11/2005Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate. Rhematoid Arthritis
Classification code 10039073		Product Code: RO0506997
INN or Proposed INN: N/A
Product Code: RO0506997
INN or Proposed INN: N/A
Product Code: RO0506997
INN or Proposed INN: N/A
Product Code: RO0506997
INN or Proposed INN: N/A		F.Hoffmann - La Roche LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		160Phase 2aSpain

Back to top